Hong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hong Wang has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Yuan Tao
Department of Ophthalmology, The Second People’s Hospital of Jinan, Jinan, China
8 shared publicationsHui Zhao
Department of Ophthalmology, Jinan Second People’s Hospital
6 shared publicationsShuting Li
Department of Ophthalmology, Qilu Hospital of Shandong Province, Jinan, China
5 shared publicationsMengyao Yang
Department of Ophthalmology, Qilu Hospital, Shandong University
4 shared publications- Shujun Fu
Shandong University
4 shared publications Yanlei Hao
Department of Ophthalmology Jinan Central Hospital of Shandong University Jinan China
4 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1875115
Efficacy of conbercept pro re nata (PRN) versus treat-and-extend (T&E) regimens following five initial monthly doses in diabetic macular edema: a 24-month retrospective cohort study
Objective: This study aimed to observe and compare the visual and anatomical improvements over 24 months in patients with diabetic macular edema (DME) treated with intravitreal conbercept injection following five initial monthly doses, using either a Pro Re Nata (PRN) regimen or a Treat-and-Extend (T&E) regimen. The injection and visit frequency were also compared between the two groups. Methods: This study retrospectively analyzed 119 patients with DME. Sixty patients received the 5+PRN regimen, while the other 59 patients were treated with the 5+T&E regimen. Baseline and post-treatment parameters, including best-corrected visual acuity (BCVA), central foveal thickness (CFT), microaneurysm count (MA count), retinal vein diameter, deep capillary plexus vessel density (DCP-VD), foveal avascular zone (FAZ) area, hard exudate (HE) area, and hemorrhage area, were recorded and compared between the two groups. The total number of intravitreal injections administered within 24 months was documented for both groups. Results: Significant improvements in BCVA, CFT, and MA count were observed as early as 6 months after treatment in both groups, and these improvements were sustained through 24 months. Significant improvements in retinal vein diameter and DCP-VD became evident at 18 months post-treatment. Both the HE area and hemorrhage area showed significant improvements at 24 months after treatment. No statistically significant change in FAZ area was detected during the follow-up period. There were no significant differences in all therapeutic outcomes between the two groups. The mean number of injections within the 24-month follow-up was 14.02 ± 2.05 in the 5+PRN group and 11.44 ± 1.74 in the 5+T&E group. Meanwhile, the average number of follow-up visits was 24.89 ± 1.67 in the 5+PRN group and 13.94 ± 2.60 in the 5+T&E group. Both the injection frequency and follow-up visits were significantly lower in the 5+T&E group than in the 5+PRN group. Conclusion: Conbercept is safe and effective for the treatment of DME. Both the 5+PRN and 5+T&E regimens demonstrated significant improvements in visual acuity and retinal anatomical structure over the 24-month follow-up period. Over 24 months, the 5+T&E group had fewer mean injections and follow-up visits compared with the 5+PRN group, indicating that an individualized dosing strategy can reduce patient burden and healthcare costs while maintaining therapeutic efficacy.
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1875115
Open AccessEfficacy of conbercept pro re nata (PRN) versus treat-and-extend (T&E) regimens following five initial monthly doses in diabetic macular edema: a 24-month retrospective cohort study
Objective: This study aimed to observe and compare the visual and anatomical improvements over 24 months in patients with diabetic macular edema (DME) treated with intravitreal conbercept injection following five initial monthly doses, using either a Pro Re Nata (PRN) regimen or a Treat-and-Extend (T&E) regimen. The injection and visit frequency were also compared between the two groups. Methods: This study retrospectively analyzed 119 patients with DME. Sixty patients received the 5+PRN regimen, while the other 59 patients were treated with the 5+T&E regimen. Baseline and post-treatment parameters, including best-corrected visual acuity (BCVA), central foveal thickness (CFT), microaneurysm count (MA count), retinal vein diameter, deep capillary plexus vessel density (DCP-VD), foveal avascular zone (FAZ) area, hard exudate (HE) area, and hemorrhage area, were recorded and compared between the two groups. The total number of intravitreal injections administered within 24 months was documented for both groups. Results: Significant improvements in BCVA, CFT, and MA count were observed as early as 6 months after treatment in both groups, and these improvements were sustained through 24 months. Significant improvements in retinal vein diameter and DCP-VD became evident at 18 months post-treatment. Both the HE area and hemorrhage area showed significant improvements at 24 months after treatment. No statistically significant change in FAZ area was detected during the follow-up period. There were no significant differences in all therapeutic outcomes between the two groups. The mean number of injections within the 24-month follow-up was 14.02 ± 2.05 in the 5+PRN group and 11.44 ± 1.74 in the 5+T&E group. Meanwhile, the average number of follow-up visits was 24.89 ± 1.67 in the 5+PRN group and 13.94 ± 2.60 in the 5+T&E group. Both the injection frequency and follow-up visits were significantly lower in the 5+T&E group than in the 5+PRN group. Conclusion: Conbercept is safe and effective for the treatment of DME. Both the 5+PRN and 5+T&E regimens demonstrated significant improvements in visual acuity and retinal anatomical structure over the 24-month follow-up period. Over 24 months, the 5+T&E group had fewer mean injections and follow-up visits compared with the 5+PRN group, indicating that an individualized dosing strategy can reduce patient burden and healthcare costs while maintaining therapeutic efficacy.
- Open Access
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1837934
Changes in retinal venous diameter in proliferative diabetic retinopathy patients with diabetic macular edema following faricimab treatment: an observational study
Introduction: To evaluate the effect of intravitreal faricimab injections on retinal venous diameter in proliferative diabetic retinopathy (PDR) patients with diabetic macular edema (DME). Methods: This single-center, retrospective cohort study included 46 PDR patients (46 eyes) with DME, treated between August 2024 and January 2025. All participants received intravitreal faricimab combined with panretinal photocoagulation (PRP). Best-corrected visual acuity (BCVA, logMAR), central foveal thickness (CFT, μm), microaneurysm (MA) count, hard exudates (HE), neovascularization (NV) area, and retinal venous diameter were assessed at baseline and at 1, 3, and 6 months post-treatment. Results: Significant improvements in BCVA were observed at 1, 3, and 6 months (0.52 ± 0.16, 0.48 ± 0.18, 0.40 ± 0.15 vs. baseline 0.66 ± 0.18; all P < 0.05). CFT showed a significant reduction at all time points (381.35 ± 40.75, 327.30 ± 43.40, 297.56 ± 35.81 μm vs. baseline 472.34 ± 47.23 μm; all P < 0.05). The MA count showed no significant reduction at 1 month (P > 0.05) but decreased significantly thereafter (72.71 ± 20.53 and 63.06 ± 17.08 at 3 and 6 months, respectively; both P < 0.05). Reductions in HE area were not significant at 1 or 3 months (in 2 and 6 patients, respectively; both P > 0.05). At 6 months, a significant reduction in HE area was observed in 14 patients (P < 0.05). The NV area was significantly reduced at 1, 3, and 6 months compared to baseline (0.17 ± 0.10 mm², 0.17 ± 0.09 mm², and 0.17 ± 0.08 mm² vs. 0.98 ± 0.17 mm²; all P 0.05) but was significantly reduced at 6 months (299.40 ± 19.56 μm; P < 0.05). Conclusion: Intravitreal faricimab was safe and effective for PDR patients with DME. A trend toward morphological reversal of retinal venous diameter was demonstrated at 6 months, suggesting that faricimab may influence retinal microvascular remodeling through dual inhibition of the VEGF-A and Ang-2 pathways.
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 17, 1837934
Open AccessChanges in retinal venous diameter in proliferative diabetic retinopathy patients with diabetic macular edema following faricimab treatment: an observational study
Introduction: To evaluate the effect of intravitreal faricimab injections on retinal venous diameter in proliferative diabetic retinopathy (PDR) patients with diabetic macular edema (DME). Methods: This single-center, retrospective cohort study included 46 PDR patients (46 eyes) with DME, treated between August 2024 and January 2025. All participants received intravitreal faricimab combined with panretinal photocoagulation (PRP). Best-corrected visual acuity (BCVA, logMAR), central foveal thickness (CFT, μm), microaneurysm (MA) count, hard exudates (HE), neovascularization (NV) area, and retinal venous diameter were assessed at baseline and at 1, 3, and 6 months post-treatment. Results: Significant improvements in BCVA were observed at 1, 3, and 6 months (0.52 ± 0.16, 0.48 ± 0.18, 0.40 ± 0.15 vs. baseline 0.66 ± 0.18; all P < 0.05). CFT showed a significant reduction at all time points (381.35 ± 40.75, 327.30 ± 43.40, 297.56 ± 35.81 μm vs. baseline 472.34 ± 47.23 μm; all P < 0.05). The MA count showed no significant reduction at 1 month (P > 0.05) but decreased significantly thereafter (72.71 ± 20.53 and 63.06 ± 17.08 at 3 and 6 months, respectively; both P < 0.05). Reductions in HE area were not significant at 1 or 3 months (in 2 and 6 patients, respectively; both P > 0.05). At 6 months, a significant reduction in HE area was observed in 14 patients (P < 0.05). The NV area was significantly reduced at 1, 3, and 6 months compared to baseline (0.17 ± 0.10 mm², 0.17 ± 0.09 mm², and 0.17 ± 0.08 mm² vs. 0.98 ± 0.17 mm²; all P 0.05) but was significantly reduced at 6 months (299.40 ± 19.56 μm; P < 0.05). Conclusion: Intravitreal faricimab was safe and effective for PDR patients with DME. A trend toward morphological reversal of retinal venous diameter was demonstrated at 6 months, suggesting that faricimab may influence retinal microvascular remodeling through dual inhibition of the VEGF-A and Ang-2 pathways.
- Open Access
- 28 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
A multi-scale feature fusion network for CNV segmentation in SD-OCT images toward quantitative assessment of neovascular AMD
Choroidal neovascularization (CNV) is a characteristic feature of neovascular age-related macular degeneration (AMD), a leading cause of irreversible visual impairment in the elderly. Accurate segmentation of CNV in spectral-domain optical coherence tomography (SD-OCT) images is crucial for quantitative assessment and treatment monitoring. However, the complex morphology and subtle boundaries of CNV lesions pose significant challenges for fully automated segmentation. In this study, we propose a deep learning-based multi-scale feature fusion network (MFF-Net) for precise and quantitative delineation of CNV in SD-OCT images. The MFF-Net integrates a multi-scale feature fusion module within an encoder-decoder architecture, effectively combining high-level semantic information with low-level details to strengthen skip connections and ensure efficient information flow. To improve boundary delineation, a gradient constraint is incorporated into the loss function, enhancing the network's ability to capture the upper edges of CNV. Furthermore, an optional interactive attention mechanism is introduced to address cases where fully automatic segmentation is insufficient. Ophthalmologists can provide minimal guidance by marking the four extreme points (top, bottom, left, and right) of the CNV region, from which a Gaussian attention heatmap is generated. This heatmap is then concatenated with the original OCT image to guide network retraining, refining the segmentation using interactive prior knowledge. Experimental results demonstrate that MFF-Net achieves reliable CNV segmentation performance. The automatic version of MFF-Net achieves the highest mean Intersection over Union (IoU) score of 0.686 among all compared methods and also outperforms them on other quantitative metrics. Remarkably, when equipped with the interactive attention module, the interactive version of MFF-Net achieves a substantial IoU improvement from 0.686 obtained by the automatic version to 0.802, demonstrating the effectiveness of the proposed interactive mechanism in enhancing segmentation accuracy. These results indicate that the proposed method provides an effective solution for accurate and efficient clinical quantitative assessment.
- 28 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessA multi-scale feature fusion network for CNV segmentation in SD-OCT images toward quantitative assessment of neovascular AMD
Choroidal neovascularization (CNV) is a characteristic feature of neovascular age-related macular degeneration (AMD), a leading cause of irreversible visual impairment in the elderly. Accurate segmentation of CNV in spectral-domain optical coherence tomography (SD-OCT) images is crucial for quantitative assessment and treatment monitoring. However, the complex morphology and subtle boundaries of CNV lesions pose significant challenges for fully automated segmentation. In this study, we propose a deep learning-based multi-scale feature fusion network (MFF-Net) for precise and quantitative delineation of CNV in SD-OCT images. The MFF-Net integrates a multi-scale feature fusion module within an encoder-decoder architecture, effectively combining high-level semantic information with low-level details to strengthen skip connections and ensure efficient information flow. To improve boundary delineation, a gradient constraint is incorporated into the loss function, enhancing the network's ability to capture the upper edges of CNV. Furthermore, an optional interactive attention mechanism is introduced to address cases where fully automatic segmentation is insufficient. Ophthalmologists can provide minimal guidance by marking the four extreme points (top, bottom, left, and right) of the CNV region, from which a Gaussian attention heatmap is generated. This heatmap is then concatenated with the original OCT image to guide network retraining, refining the segmentation using interactive prior knowledge. Experimental results demonstrate that MFF-Net achieves reliable CNV segmentation performance. The automatic version of MFF-Net achieves the highest mean Intersection over Union (IoU) score of 0.686 among all compared methods and also outperforms them on other quantitative metrics. Remarkably, when equipped with the interactive attention module, the interactive version of MFF-Net achieves a substantial IoU improvement from 0.686 obtained by the automatic version to 0.802, demonstrating the effectiveness of the proposed interactive mechanism in enhancing segmentation accuracy. These results indicate that the proposed method provides an effective solution for accurate and efficient clinical quantitative assessment.
- Open Access
- 18 March 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-2
Correction: Enhancing diabetic retinopathy diagnosis: automatic segmentation of hyperreflective foci in OCT via deep learning
- 18 March 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-2
Open AccessCorrection: Enhancing diabetic retinopathy diagnosis: automatic segmentation of hyperreflective foci in OCT via deep learning
- Open Access
- 18 February 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-18
Enhancing diabetic retinopathy diagnosis: automatic segmentation of hyperreflective foci in OCT via deep learning
Objective: Hyperreflective foci (HRF) are small, punctate lesions ranging from 20 to 50 $$\mu$$ m and exhibiting high reflective intensity in optical coherence tomography (OCT) images of patients with diabetic retinopathy (DR). The purpose of the model proposed in this paper is to precisely identify and segment the HRF in OCT images of patients with DR. This method is essential for assisting ophthalmologists in the early diagnosis and assessing the effectiveness of treatment and prognosis. In this study, we introduce an HRF segmentation algorithm based on KiU-Net, the algorithm that comprises the Kite-Net branch using up-sampling coding to collect more detailed information and a three-layer U-Net branch to extract high-level semantic information. To enhance the capacity of a single-branch network, we also design a cross-attention block (CAB) which combines the information extracted from two branches. The experimental results demonstrate that the number of parameters of our model is significantly reduced, and the sensitivity (SE) and the dice similarity coefficient (DSC) are respectively improved to 72.90 $$\%$$ and 66.84 $$\%$$ . Considering the SE and precision(P) of the segmentation, as well as the recall ratio and recall P of HRF, we believe that this model outperforms most advanced medical image segmentation algorithms and significantly relieves the strain on ophthalmologists. Purpose: Hyperreflective foci (HRF) are small, punctate lesions ranging from 20 to 50 μm with high reflective intensity in optical coherence tomography (OCT) images of patients with diabetic retinopathy (DR). This study aims to develop a model that precisely identifies and segments HRF in OCT images of DR patients. Accurate segmentation of HRF is essential for assisting ophthalmologists in early diagnosis and in assessing the effectiveness of treatment and prognosis. Methods: We introduce an HRF segmentation algorithm based on the KiU-Net architecture. The model comprises two branches: a Kite-Net branch that uses up-sampling coding to capture detailed information, and a three-layer U-Net branch that extracts high-level semantic information. To enhance the capacity of the network, we designed a cross-attention block (CAB) that combines the information extracted from both branches, effectively integrating detail and semantic features. Results: Experimental results demonstrate that our model significantly reduces the number of parameters while improving performance. The sensitivity (SE) and Dice Similarity Coefficient (DSC) of our model are improved to 72.90% and 66.84%, respectively. Considering the SE and precision (P) of the segmentation, as well as the recall ratio and precision of HRF detection, our model outperforms most advanced medical image segmentation algorithms Conclusion: The proposed HRF segmentation algorithm effectively identifies and segments HRF in OCT images of DR patients, outperforming existing methods. This advancement can significantly alleviate the burden on ophthalmologists by aiding in early diagnosis and treatment evaluation, ultimately improving patient outcomes.- 18 February 2025
- Published by Springer Nature in International Ophthalmology
- Vol. 45 (1) , 1-18
Open AccessEnhancing diabetic retinopathy diagnosis: automatic segmentation of hyperreflective foci in OCT via deep learning
Objective: Hyperreflective foci (HRF) are small, punctate lesions ranging from 20 to 50 $$\mu$$ m and exhibiting high reflective intensity in optical coherence tomography (OCT) images of patients with diabetic retinopathy (DR). The purpose of the model proposed in this paper is to precisely identify and segment the HRF in OCT images of patients with DR. This method is essential for assisting ophthalmologists in the early diagnosis and assessing the effectiveness of treatment and prognosis. In this study, we introduce an HRF segmentation algorithm based on KiU-Net, the algorithm that comprises the Kite-Net branch using up-sampling coding to collect more detailed information and a three-layer U-Net branch to extract high-level semantic information. To enhance the capacity of a single-branch network, we also design a cross-attention block (CAB) which combines the information extracted from two branches. The experimental results demonstrate that the number of parameters of our model is significantly reduced, and the sensitivity (SE) and the dice similarity coefficient (DSC) are respectively improved to 72.90 $$\%$$ and 66.84 $$\%$$ . Considering the SE and precision(P) of the segmentation, as well as the recall ratio and recall P of HRF, we believe that this model outperforms most advanced medical image segmentation algorithms and significantly relieves the strain on ophthalmologists. Purpose: Hyperreflective foci (HRF) are small, punctate lesions ranging from 20 to 50 μm with high reflective intensity in optical coherence tomography (OCT) images of patients with diabetic retinopathy (DR). This study aims to develop a model that precisely identifies and segments HRF in OCT images of DR patients. Accurate segmentation of HRF is essential for assisting ophthalmologists in early diagnosis and in assessing the effectiveness of treatment and prognosis. Methods: We introduce an HRF segmentation algorithm based on the KiU-Net architecture. The model comprises two branches: a Kite-Net branch that uses up-sampling coding to capture detailed information, and a three-layer U-Net branch that extracts high-level semantic information. To enhance the capacity of the network, we designed a cross-attention block (CAB) that combines the information extracted from both branches, effectively integrating detail and semantic features. Results: Experimental results demonstrate that our model significantly reduces the number of parameters while improving performance. The sensitivity (SE) and Dice Similarity Coefficient (DSC) of our model are improved to 72.90% and 66.84%, respectively. Considering the SE and precision (P) of the segmentation, as well as the recall ratio and precision of HRF detection, our model outperforms most advanced medical image segmentation algorithms Conclusion: The proposed HRF segmentation algorithm effectively identifies and segments HRF in OCT images of DR patients, outperforming existing methods. This advancement can significantly alleviate the burden on ophthalmologists by aiding in early diagnosis and treatment evaluation, ultimately improving patient outcomes. - Open Access
- 5 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 650-660
The reduction of LEDD leads to visual dysfunction in patients with PD after STN-DBS: a randomized clinical trial
Background: Medication adjustment after deep brain stimulation (DBS) of the subthalamic nucleus (STN) in patients with Parkinson’s disease (PD) may influence visual function. However, no clinical trials have been designed specifically to investigate this effect. Objectives: To compare the effects of levodopa-equivalent daily dose (LEDD) reduction and non-reduction on visual function in patients with Parkinson’s disease (PD) following STN-DBS. Methods: This was a multi-center, prospective, randomized, double-blinded clinical trial. A total of 208 patients with Parkinson’s disease were referred for DBS between June 2019 and July 2021 and analyzed between June 2023 and July 2023. STN-DBS was performed, and the LEDD was reduced in one study arm but not in the other. The primary outcome measure was visual impairment in Parkinson’s disease questionnaire (VIPD-Q) with or without LEDD reduction 12 months postoperatively, and the secondary outcomes included retinal nerve fiber layer (RNFL) thickness, vessel density, eye-tracking system results, contrast sensitivity and visual field. Results: During the short-term follow-up, DBS implantation and stimulation did not significantly affect visual function (VIPD-Q, baseline vs. 1 month, 9.269±8.385 vs. 8.938±7.666, Mann–Whitney U tests; P =0.6746). In the long-term follow-up, the reduction group demonstrated a significant decline in visual function, RNFL thickness, and vessel density after STN-DBS compared with the control group without STN-DBS ( P <0.001). Conclusions: Visual dysfunction, particularly a thinner RNFL and lower vessel density, is related to LEDD reduction after STN-DBS. Prolonged administration of dopamine-mimetic drugs prevents visual symptoms. Thus, physicians should consider LEDD adjustment when patients report visual dysfunction before surgery or severe visual symptoms after STN-DBS.
- 5 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 650-660
Open AccessThe reduction of LEDD leads to visual dysfunction in patients with PD after STN-DBS: a randomized clinical trial
Background: Medication adjustment after deep brain stimulation (DBS) of the subthalamic nucleus (STN) in patients with Parkinson’s disease (PD) may influence visual function. However, no clinical trials have been designed specifically to investigate this effect. Objectives: To compare the effects of levodopa-equivalent daily dose (LEDD) reduction and non-reduction on visual function in patients with Parkinson’s disease (PD) following STN-DBS. Methods: This was a multi-center, prospective, randomized, double-blinded clinical trial. A total of 208 patients with Parkinson’s disease were referred for DBS between June 2019 and July 2021 and analyzed between June 2023 and July 2023. STN-DBS was performed, and the LEDD was reduced in one study arm but not in the other. The primary outcome measure was visual impairment in Parkinson’s disease questionnaire (VIPD-Q) with or without LEDD reduction 12 months postoperatively, and the secondary outcomes included retinal nerve fiber layer (RNFL) thickness, vessel density, eye-tracking system results, contrast sensitivity and visual field. Results: During the short-term follow-up, DBS implantation and stimulation did not significantly affect visual function (VIPD-Q, baseline vs. 1 month, 9.269±8.385 vs. 8.938±7.666, Mann–Whitney U tests; P =0.6746). In the long-term follow-up, the reduction group demonstrated a significant decline in visual function, RNFL thickness, and vessel density after STN-DBS compared with the control group without STN-DBS ( P <0.001). Conclusions: Visual dysfunction, particularly a thinner RNFL and lower vessel density, is related to LEDD reduction after STN-DBS. Prolonged administration of dopamine-mimetic drugs prevents visual symptoms. Thus, physicians should consider LEDD adjustment when patients report visual dysfunction before surgery or severe visual symptoms after STN-DBS.
- Open Access
- 22 February 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1286736
Aflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial
Objective: This study aimed to investigate and compare the efficacy and safety of retinal laser photocoagulation (PRP) alone, PRP with aflibercept 3+PRN, and PRP with aflibercept 5+PRN in patients with both high-risk proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME).Methods: Overall, 170 patients with high-risk PDR and DME (170 eyes from 170 patients) who visited our ophthalmology clinic from December 2018 to December 2020 were divided into the PRP (n=58), aflibercept 5+PRN with PRP (n=53), and aflibercept 3+PRN with PRP (n= 59) groups. General information, such as age, sex, and eye category, was obtained. Moreover, best-corrected visual acuity (BCVA), baseline central macular foveal thickness (CFT), microaneurysm (MA), area of neovascularization (NV), area of hard exudate (HE), and cytokine levels in atrial fluid before and after treatment, were assessed. The χ2 test was used for comparison between groups for statistical data. Analysis of variance was used for the statistical description of measurement data, independent samples were analyzed using Student’s t-test, and Student–Newman–Keuls test was used for group comparisons. Differences were considered statistically significant at P < 0.05.Results: After treatment, no significant improvement in the BCVA (logMAR) of patients in the PRP group was observed. The BCVA (log MAR) decreased from 0.72 ± 0.17 and 0.74 ± 0.17 to 0.50 ± 0.13 and 0.53 ± 0.17 in PRP with aflibercept 5+PRN and PRP with aflibercept 3+PRN groups, respectively, with a statistically significant difference compared to those in the PRP group (P0.05). The CFT in the PRP-only group decreased slightly from 361.80 ± 36.70 μm to 353.86 ± 40.88 μm, with no statistically significant difference (P>0.05), whereas the CFT in the aflibercept 5+PRN with PRP and aflibercept 3+PRN with PRP groups decreased from 356.57 ± 37.57 μm and 358.17 ± 44.66 μm to 284.87 ± 31.52 μm and 303.19 ± 37.00 μm, respectively, with statistically significant differences before and after treatment (P<0.05 for both groups). Statistically significant differences were observed in CFT between the three groups after treatment (P<0.05 in all cases). The number of MA (pcs) in the PRP, aflibercept 5+PRN with PRP, and aflibercept 3+PRN with PRP groups decreased from 118.34 ± 27.96, 118.60 ± 33.34, and 116.59 ± 28.95 to 92.95 ± 29.04, 44.60 ± 20.73, and 54.26 ± 25.43, respectively. The two-way comparison of the three groups revealed statistically significant differences in MA (P<0.05 in all cases). In the three groups, NV decreased from 1.00 ± 0.21 mm², 1.01 ± 0.18 mm², and 0.98 ± 0.20 mm² before treatment to 0.49 ± 0.17 mm², 0.31 ± 0.16 mm², and 0.38 ± 0.14 mm², respectively, with statistically significant differences (P<0.05 in all cases). After 12 months of treatment, 13, 18, and 18 patients had reduced HE area in the PRP-only, aflibercept 5+PRN with PRP, and aflibercept 3+PRN with PRP groups, respectively, with statistically significant differences (P0.05).Conclusion: Aflibercept 5+PRN combined with PRP was safe and effective in treating patients with high-risk PDR and DME, and was more effective than PRP-only and aflibercept 3+PRN with PRP in improving CFT and MA.
- 22 February 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1286736
Open AccessAflibercept 5+PRN with retinal laser photocoagulation is more effective than retinal laser photocoagulation alone and aflibercept 3+PRN with retinal laser photocoagulation in patients with high-risk proliferative diabetic retinopathy and diabetic macular edema: a 12-month clinical trial
Objective: This study aimed to investigate and compare the efficacy and safety of retinal laser photocoagulation (PRP) alone, PRP with aflibercept 3+PRN, and PRP with aflibercept 5+PRN in patients with both high-risk proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME).Methods: Overall, 170 patients with high-risk PDR and DME (170 eyes from 170 patients) who visited our ophthalmology clinic from December 2018 to December 2020 were divided into the PRP (n=58), aflibercept 5+PRN with PRP (n=53), and aflibercept 3+PRN with PRP (n= 59) groups. General information, such as age, sex, and eye category, was obtained. Moreover, best-corrected visual acuity (BCVA), baseline central macular foveal thickness (CFT), microaneurysm (MA), area of neovascularization (NV), area of hard exudate (HE), and cytokine levels in atrial fluid before and after treatment, were assessed. The χ2 test was used for comparison between groups for statistical data. Analysis of variance was used for the statistical description of measurement data, independent samples were analyzed using Student’s t-test, and Student–Newman–Keuls test was used for group comparisons. Differences were considered statistically significant at P < 0.05.Results: After treatment, no significant improvement in the BCVA (logMAR) of patients in the PRP group was observed. The BCVA (log MAR) decreased from 0.72 ± 0.17 and 0.74 ± 0.17 to 0.50 ± 0.13 and 0.53 ± 0.17 in PRP with aflibercept 5+PRN and PRP with aflibercept 3+PRN groups, respectively, with a statistically significant difference compared to those in the PRP group (P0.05). The CFT in the PRP-only group decreased slightly from 361.80 ± 36.70 μm to 353.86 ± 40.88 μm, with no statistically significant difference (P>0.05), whereas the CFT in the aflibercept 5+PRN with PRP and aflibercept 3+PRN with PRP groups decreased from 356.57 ± 37.57 μm and 358.17 ± 44.66 μm to 284.87 ± 31.52 μm and 303.19 ± 37.00 μm, respectively, with statistically significant differences before and after treatment (P<0.05 for both groups). Statistically significant differences were observed in CFT between the three groups after treatment (P<0.05 in all cases). The number of MA (pcs) in the PRP, aflibercept 5+PRN with PRP, and aflibercept 3+PRN with PRP groups decreased from 118.34 ± 27.96, 118.60 ± 33.34, and 116.59 ± 28.95 to 92.95 ± 29.04, 44.60 ± 20.73, and 54.26 ± 25.43, respectively. The two-way comparison of the three groups revealed statistically significant differences in MA (P<0.05 in all cases). In the three groups, NV decreased from 1.00 ± 0.21 mm², 1.01 ± 0.18 mm², and 0.98 ± 0.20 mm² before treatment to 0.49 ± 0.17 mm², 0.31 ± 0.16 mm², and 0.38 ± 0.14 mm², respectively, with statistically significant differences (P<0.05 in all cases). After 12 months of treatment, 13, 18, and 18 patients had reduced HE area in the PRP-only, aflibercept 5+PRN with PRP, and aflibercept 3+PRN with PRP groups, respectively, with statistically significant differences (P0.05).Conclusion: Aflibercept 5+PRN combined with PRP was safe and effective in treating patients with high-risk PDR and DME, and was more effective than PRP-only and aflibercept 3+PRN with PRP in improving CFT and MA.
- Open Access
- 20 September 2023
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 51 (9)
Retinal artery occlusion after facial filler injection in a patient with patent foramen ovale: a case report and literature review
We describe a young woman with patent foramen ovale who developed multiple retinal artery occlusion in the right eye after injection of hyaluronic acid into the nasal root. She reported a gradual decline in visual acuity, with visual field defects that had developed in two stages. Multiple retinal artery occlusion was confirmed by slit-lamp examination, dilated fundus examination, optical coherence tomography, visual field examination, and fundus fluorescein angiography. A patent foramen ovale was detected by electrocardiography, transesophageal echocardiography, and transthoracic sonography. The patient was treated with intravenous dexamethasone and cobamamide, as well as extracorporeal counterpulsation therapy; this approach has not been described in previous literature regarding retinal artery occlusion. The patient’s visual acuity improved from counting fingers at 30 cm to 20/133 within 3 days. Our report emphasizes the need for better understanding of vascular anatomy to minimize the risk of complications. Moreover, patients undergoing hyaluronic acid injection should receive information regarding the potential for mild and severe complications; relevant tests should be performed before surgery to exclude vulnerable patients. Finally, a nursing system is needed to facilitate the emergency recognition, triage, and management of retinal artery occlusion.
- 20 September 2023
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 51 (9)
Open AccessRetinal artery occlusion after facial filler injection in a patient with patent foramen ovale: a case report and literature review
We describe a young woman with patent foramen ovale who developed multiple retinal artery occlusion in the right eye after injection of hyaluronic acid into the nasal root. She reported a gradual decline in visual acuity, with visual field defects that had developed in two stages. Multiple retinal artery occlusion was confirmed by slit-lamp examination, dilated fundus examination, optical coherence tomography, visual field examination, and fundus fluorescein angiography. A patent foramen ovale was detected by electrocardiography, transesophageal echocardiography, and transthoracic sonography. The patient was treated with intravenous dexamethasone and cobamamide, as well as extracorporeal counterpulsation therapy; this approach has not been described in previous literature regarding retinal artery occlusion. The patient’s visual acuity improved from counting fingers at 30 cm to 20/133 within 3 days. Our report emphasizes the need for better understanding of vascular anatomy to minimize the risk of complications. Moreover, patients undergoing hyaluronic acid injection should receive information regarding the potential for mild and severe complications; relevant tests should be performed before surgery to exclude vulnerable patients. Finally, a nursing system is needed to facilitate the emergency recognition, triage, and management of retinal artery occlusion.
- Open Access
- 25 August 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1218442
Retinal vein changes in patients with high-risk proliferative diabetic retinopathy treated with conbercept and panretinal photocoagulation co-therapy: a cohort study
Objective: This study aimed to observe and compare retinal vein diameter changes and other essential indicators in patients with high-risk proliferative diabetic retinopathy (PDR) treated with intravitreal injection of conbercept (IVC) combined with panretinal photocoagulation (PRP) versus PRP monotherapy.Methods: A retrospective analysis was conducted on data from patients with high-risk PDR who received specific treatment and were followed up for 24 months. Among 82 patients with high-risk PDR, 50 eyes received PRP combined with IVC, whereas 32 eyes received PRP alone. During the 24-month follow-up period, changes in best-corrected visual acuity (BCVA), central foveal thickness (CFT), retinal vein diameter, number of microaneurysms (MA), neovascularization (NV) area, hard exudate (HE) area, size of the foveal avascular zone (FAZ), superficial capillary plexus (SCP) blood flow density, and adverse effects were recorded and compared between the two groups at baseline and at 6, 12, 18, and 24 months after treatment. The relationship between each observation index and vein diameter was also analyzed.Results: During the 24-month follow up, significant improvements in the BCVA, CFT, retinal vein diameter, number of MAs, NV area, HE area, FAZ, and SCP were observed in the IVC+PRP group after treatment. The PRP group only showed significant reductions in NV and HE areas. The IVC+PRP group showed significant superiority over the PRP group in improving the vein diameter, number of MA, and HE area. However, no statistically significant difference in NV area reduction was found between the groups.Conclusion: In the treatment of high-risk PDR, IVC+PRP therapy has a significant advantage over PRP monotherapy. IVC+PRP therapy may reverse diabetes-induced retinal vein changes, restoring morphology and function.
- 25 August 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 14, 1218442
Open AccessRetinal vein changes in patients with high-risk proliferative diabetic retinopathy treated with conbercept and panretinal photocoagulation co-therapy: a cohort study
Objective: This study aimed to observe and compare retinal vein diameter changes and other essential indicators in patients with high-risk proliferative diabetic retinopathy (PDR) treated with intravitreal injection of conbercept (IVC) combined with panretinal photocoagulation (PRP) versus PRP monotherapy.Methods: A retrospective analysis was conducted on data from patients with high-risk PDR who received specific treatment and were followed up for 24 months. Among 82 patients with high-risk PDR, 50 eyes received PRP combined with IVC, whereas 32 eyes received PRP alone. During the 24-month follow-up period, changes in best-corrected visual acuity (BCVA), central foveal thickness (CFT), retinal vein diameter, number of microaneurysms (MA), neovascularization (NV) area, hard exudate (HE) area, size of the foveal avascular zone (FAZ), superficial capillary plexus (SCP) blood flow density, and adverse effects were recorded and compared between the two groups at baseline and at 6, 12, 18, and 24 months after treatment. The relationship between each observation index and vein diameter was also analyzed.Results: During the 24-month follow up, significant improvements in the BCVA, CFT, retinal vein diameter, number of MAs, NV area, HE area, FAZ, and SCP were observed in the IVC+PRP group after treatment. The PRP group only showed significant reductions in NV and HE areas. The IVC+PRP group showed significant superiority over the PRP group in improving the vein diameter, number of MA, and HE area. However, no statistically significant difference in NV area reduction was found between the groups.Conclusion: In the treatment of high-risk PDR, IVC+PRP therapy has a significant advantage over PRP monotherapy. IVC+PRP therapy may reverse diabetes-induced retinal vein changes, restoring morphology and function.
- Open Access
- 9 March 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1090964
Retinal vein changes after treatment with aflibercept and PRP in high-risk proliferative diabetic retinopathy
Objective: The objective of the study was to investigate the effectiveness of aflibercept and panretinal photocoagulation (PRP) in the treatment of proliferative diabetic retinopathy (PDR).Methods: A retrospective analysis was performed on 59 patients (59 eyes) with high-risk PDR who were treated with aflibercept and PRP between January 2018 and December 2019. The best corrected visual acuity (BCVA), central foveal thickness (CFT), and retinal vein diameter post-treatment were compared to those before the treatment.Results: The best corrected visual acuity (BCVA) at 6 months (0.49 ± 0.14 logMAR), 12 months (0.54 ± 0.15 logMAR), 18 months (0.48 ± 0.15 logMAR), and 24 months (0.51 ± 0.15 logMAR) post-treatment were superior to the pre-treatment measurement (0.65 ± 0.18 logMAR). The central foveal thickness (CFT) at 6 months (310.67 ± 52.53 μm), 12 months (295.98 ± 45.65 μm), 18 months (282.56 ± 43.57 μm), and 24 months (281.53 ± 51.16 μm) post-treatment were lower than the pre-treatment measurement (456.53 ± 51.49 μm); the retinal vein diameter at 12 months (310.13 ± 24.60 μm), 18 months (309.50 ± 31.58 μm), and 24 months (317.00 ± 27.54 μm) post-treatment were lower than the pre-treatment measurement (361.81 ± 30.26 μm).Conclusion: Aflibercept intravitreal injection and panretinal photocoagulation may morphologically reverse retinal vein diameter and venous beading in high-risk proliferative diabetic retinopathy.
- 9 March 2023
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 10, 1090964
Open AccessRetinal vein changes after treatment with aflibercept and PRP in high-risk proliferative diabetic retinopathy
Objective: The objective of the study was to investigate the effectiveness of aflibercept and panretinal photocoagulation (PRP) in the treatment of proliferative diabetic retinopathy (PDR).Methods: A retrospective analysis was performed on 59 patients (59 eyes) with high-risk PDR who were treated with aflibercept and PRP between January 2018 and December 2019. The best corrected visual acuity (BCVA), central foveal thickness (CFT), and retinal vein diameter post-treatment were compared to those before the treatment.Results: The best corrected visual acuity (BCVA) at 6 months (0.49 ± 0.14 logMAR), 12 months (0.54 ± 0.15 logMAR), 18 months (0.48 ± 0.15 logMAR), and 24 months (0.51 ± 0.15 logMAR) post-treatment were superior to the pre-treatment measurement (0.65 ± 0.18 logMAR). The central foveal thickness (CFT) at 6 months (310.67 ± 52.53 μm), 12 months (295.98 ± 45.65 μm), 18 months (282.56 ± 43.57 μm), and 24 months (281.53 ± 51.16 μm) post-treatment were lower than the pre-treatment measurement (456.53 ± 51.49 μm); the retinal vein diameter at 12 months (310.13 ± 24.60 μm), 18 months (309.50 ± 31.58 μm), and 24 months (317.00 ± 27.54 μm) post-treatment were lower than the pre-treatment measurement (361.81 ± 30.26 μm).Conclusion: Aflibercept intravitreal injection and panretinal photocoagulation may morphologically reverse retinal vein diameter and venous beading in high-risk proliferative diabetic retinopathy.